Physicians' Academy for Cardiovascular Education

Increase in LDL may not always be associated with increase in CV risk

3' education - May 25, 2015 - ISA Amsterdam, May 25, 2015 - Allyson Morton



ISA2015 | Clinical Breakthroughs Allyson Morton (Boston, USA) presented a follow-up study of the EVOLVE trial, which showed that omega-3 carboxylic acid treatment reduced apoCIII levels in whole plasma, and in HDL and LDL. LDL levels without apoCIII were reduced, which has a weak relation to CV risk.

The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.

Share this page with your colleagues and friends: